CAR T-cell Therapy for B-cell Lymphomas: Clinical Trial Results of Available Products

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2019 Apr 26

PMID 31019670

Citations 116

Authors

Julio C Chavez

Christina Bachmeier

Mohamed A Kharfan-Dabaja

Affiliations

Soon will be listed here.

Abstract

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. Two CAR T-cell products [axicabtagene ciloleucel (axi-cel) and tisagenlecleucel] have obtained US Food and Drug Administration approval for the treatment of refractory DLBCL after two lines of therapy. A third product, liso-cel, is currently being evaluated in clinical trials and preliminary results appear very promising. CAR T-cell-related toxicity with cytokine-release syndrome and neurotoxicity remain important potential complications of this therapy. Here, we review the s biology, structure, clinical trial results and toxicity of two commercially approved CAR T-cell products and others currently being studied in multicenter clinical trials in B-cell NHLs.

Citing Articles

Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.

Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H Front Immunol. 2025; 16:1544532.

PMID: 40046061 PMC: 11880241. DOI: 10.3389/fimmu.2025.1544532.

TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model.

Kim Y, Jeun M, Lee H, Choi J, Park S, Park C Exp Hematol Oncol. 2025; 14(1):23.

PMID: 40012079 PMC: 11866829. DOI: 10.1186/s40164-025-00609-8.

Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.

Kanbay M, Mizrak B, Alper E, Copur S, Ortiz A Clin Kidney J. 2025; 18(1):sfae359.

PMID: 39781479 PMC: 11704793. DOI: 10.1093/ckj/sfae359.

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system.

Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q J Hematol Oncol. 2024; 17(1):122.

PMID: 39696585 PMC: 11657976. DOI: 10.1186/s13045-024-01648-0.

How lactate affects immune strategies in lymphoma.

Zhou Y, Lou J, Tian Y, Ding J, Wang X, Tang B Front Mol Biosci. 2024; 11:1480884.

PMID: 39464313 PMC: 11502318. DOI: 10.3389/fmolb.2024.1480884.

References

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Andersen N, Jensen M, de Nully Brown P, Geisler C . A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer. 2002; 38(3):401-8. DOI: 10.1016/s0959-8049(01)00366-5. View

Brentjens R, Latouche J, Santos E, Marti F, Gong M, Lyddane C . Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003; 9(3):279-86. DOI: 10.1038/nm827. View

Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R . Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. DOI: 10.1182/blood-2003-12-4434. View

Morton L, Wang S, Devesa S, Hartge P, Weisenburger D, Linet M . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2005; 107(1):265-76. PMC: 1895348. DOI: 10.1182/blood-2005-06-2508. View

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, Van Hoof A, Kluin-Nelemans H . A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2007; 111(2):558-65. DOI: 10.1182/blood-2007-06-095331. View

Khouri I, McLaughlin P, Saliba R, Hosing C, Korbling M, Lee M . Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008; 111(12):5530-6. PMC: 4624452. DOI: 10.1182/blood-2008-01-136242. View

James S, Greenberg P, Jensen M, Lin Y, Wang J, Till B . Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008; 180(10):7028-38. PMC: 2585549. DOI: 10.4049/jimmunol.180.10.7028. View

Till B, Jensen M, Wang J, Chen E, Wood B, Greisman H . Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112(6):2261-71. PMC: 2532803. DOI: 10.1182/blood-2007-12-128843. View

10.

Geisler C, Kolstad A, Laurell A, Andersen N, Pedersen L, Jerkeman M . Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008; 112(7):2687-93. PMC: 2556606. DOI: 10.1182/blood-2008-03-147025. View

11.

Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23. PMC: 9103713. DOI: 10.1056/NEJMoa0802885. View

12.

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View

13.

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555-62. DOI: 10.1200/JCO.2008.21.3991. View

14.

Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti G . Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2009; 147(5):719-28. DOI: 10.1111/j.1365-2141.2009.07905.x. View

15.

Jensen M, Popplewell L, Cooper L, DiGiusto D, Kalos M, Ostberg J . Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010; 16(9):1245-56. PMC: 3383803. DOI: 10.1016/j.bbmt.2010.03.014. View

16.

Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R . Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28(20):3360-5. DOI: 10.1200/JCO.2009.26.3947. View

17.

Coiffier B, Thieblemont C, Van den Neste E, Lepeu G, Plantier I, Castaigne S . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12):2040-5. PMC: 2951853. DOI: 10.1182/blood-2010-03-276246. View

18.

Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-102. PMC: 2993617. DOI: 10.1182/blood-2010-04-281931. View

19.

Salles G, Seymour J, Offner F, Lopez-Guillermo A, Belada D, Xerri L . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2010; 377(9759):42-51. DOI: 10.1016/S0140-6736(10)62175-7. View

20.

van Kampen R, Canals C, Schouten H, Nagler A, Thomson K, Vernant J . Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation.... J Clin Oncol. 2011; 29(10):1342-8. DOI: 10.1200/JCO.2010.30.2596. View